Scientific data on controversial subjects are commonly misinterpreted, overinterpreted, and misrepresented, and the medical marijuana debate is no exception. We have tried to present the scientific studies in such a way as to reveal their strengths and limitations. One of the goals of this report is to help people to understand the scientific data, including the logic behind the scientific conclusions, so it goes into greater detail than previous reports on the subject. In many cases, we have explained why particular studies are inconclusive and what sort of evidence is needed to support particular claims about the harms or benefits attributed to marijuana.
In context of more states voting in favor of marijuana use legalization and business interest sparking across the board, that definitely would make sense.
Given that is not exactly an apples to apples comparison, but it does make a case to at least investigate investments in marijuana stocks. But before you open your wallet to get a piece of the action, here are a few things that could help you.
In the midterm elections that were held on November 6,the following states voted in favor of marijuana legalization for either recreational or medicinal purposes, or both: Voters approved Proposal One, which legalizes marijuana use and cultivation for people over the age of 21 in addition to authorizing the commercial sale of marijuana through state-licensed retailers.
Voters approved Amendment 2, which permits the use of marijuana for medical purposes and allows patients to cultivate plants at home. Marijuana was not approved for recreational use. Voters approved Propostion Two, which allows some use of marijuana for medical purposes, only.
On June 26, Oklahoma voted to in favor of legalizing marijuana for medical use, becoming the 30th state in the country to do so.
But validity of these state laws depends on the stance of the federal government that has not quite landed firmly on one side. In January ofAttorney General Jeff Sessions, a vocal opponent of marijuana legalization, rescinded an Obama-era rule that gave states a greater role in marijuana law enforcement though it conceded that states could not come in the way of any federal enforcement action.
The state of regulation will, needless to say, determine the fate of this industry. As the legal boundaries exist today, many companies are witnessing exponential growth on the back of surging demand and interest.
This momentum could continue till there is more clarity on regulations. This uncertainty in the regulatory framework has not only impacted business operations for companies in the sector but has also seen fewer listings in the United States. In fact, there have been cases where American companies have gone north in search of more welcoming environment for their stock market debut.
Even as the bigger exchanges open up to companies in this space, a large number of companies remain penny stocks being traded primarily in the OTC Markets, increasing both skepticism as well as risk perception of any investment.
What to Watch Out For As with any other investment, investors must do their homework before they place their bets. That can be hard, since a lot of these companies trade in the OTC Markets with less stringent filing and disclosure requirements compared to the larger exchanges.
It can also be difficult to understand business models and source information about investments since the industry is still young and still not mainstream. And having said that, there are some less than stellar names in the New York Stock Exchange trading there," said Debra Borchardt, Founder and Editor-in-chief of Greenmarketsreport.
The company received the FDA approval for its drug Syndros in The interesting thing is that he company has no revenue. Investors would need to factor that in before making a decision of investing in the company. The company owns and operates many brands, producing and marketing both medical and recreational strains.
For the fiscal year ended March In OctoberConstellation Brands, beverage giant and maker of Corona beer, bought 9.Medical cannabis, or medical marijuana, is cannabis and cannabinoids that are recommended by doctors for their patients.
The use of cannabis as medicine has not been rigorously tested due to production restrictions and other governmental regulations. Limited evidence suggests that cannabis can reduce nausea and vomiting during chemotherapy, improve appetite in people with HIV/AIDS, and . The U.S.
Food and Drug Administration (FDA) has not recognized or approved the marijuana plant as medicine. However, scientific study of the chemicals in marijuana caused the decrease in deaths or that pain patients changed their drug-taking behavior.
4,5 A more detailed NIDA-funded analysis showed that legally protected medical. Victoria University of Wellington research shows there has been almost no change to the level of crime in the United States since the legalisation of medical marijuana.
Use of marijuana as medicine also poses other problems such as the adverse health effects of smoking and THC-induced cognitive impairment.
in each year following the implementation of legislation. 81 The second NIDA-funded study was a more detailed analysis by the RAND Corporation that showed legally protected access to medical .
Several studies have linked marijuana use to increased risk for psychiatric disorders, including psychosis (schizophrenia), depression, anxiety, and substance use disorders, but whether and to what extent it actually causes these conditions is not always easy to determine.
32 The amount of drug used, the age at first use, and genetic vulnerability have all been shown to influence this. Presented in part at the Society of General Internal Medicine Annual Meeting, Denver, Colorado, 11–14 April Note: Dr. Keyhani had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Grant Support: This project was not directly supported by any funds. Dr.